A comparison of TET2 transcripts between normal and malignant prostate and breast tissues revealed significantly lower levels of TET2 mRNA in prostate cancer cell lines as compared to normal tissue, but not in breast cancer cell lines, suggesting that downregulation of TET2 may be a common event in prostate cancer (Figure 4B). The gene discussed is TET2; the disease is prostate carcinoma.